{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:05:01Z","timestamp":1784016301158,"version":"3.55.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["EEQ\/2022\/000219"],"award-info":[{"award-number":["EEQ\/2022\/000219"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.nano.2026.102961","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:50:52Z","timestamp":1779925852000},"page":"102961","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Rationally designed, synthesized, and characterization of anti-PD-L1 peptide conjugated temozolomide self-assembled prodrug nanoparticles for targeted lung cancer chemoimmunotherapy"],"prefix":"10.1016","volume":"75","author":[{"given":"Sakuntala","family":"Gayen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumendra Nath","family":"Bandyopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandipan","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2980-0362","authenticated-orcid":false,"given":"Souvik","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.nano.2026.102961_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.nano.2026.102961_bb0010","first-page":"189","article-title":"Lung cancer: Biology and treatment options","volume":"1856","author":"Lemjabbar-Alaoui","year":"2015","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"10.1016\/j.nano.2026.102961_bb0015","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.3390\/ijms26052049","article-title":"Lung Cancer\u2014Epidemiology, Pathogenesis, Treatment and Molecular Aspect (Review of Literature)","volume":"26","author":"Smolarz","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nano.2026.102961_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.109821","article-title":"Cancer immunotherapy: pros, cons and beyond","volume":"124","author":"Tan","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.nano.2026.102961_bb0025","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.nano.2026.102961_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1383456","article-title":"Targeting PD-1\/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges","volume":"15","author":"Javed","year":"2024","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.nano.2026.102961_bb0035","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ccell.2020.07.004","article-title":"Clinical Challenges of Immune Checkpoint Inhibitors","volume":"38","author":"de Miguel","year":"2020","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.nano.2026.102961_bb0040","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s11886-021-01530-2","article-title":"Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors","volume":"23","author":"Lee","year":"2021","journal-title":"Curr Cardiol Rep"},{"issue":"12","key":"10.1016\/j.nano.2026.102961_bb0045","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.nano.2026.102961_bb0050","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jconrel.2023.05.031","article-title":"Immune checkpoint-targeted drug conjugates: A promising tool for remodeling tumor immune microenvironment","volume":"359","author":"Choi","year":"2023","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2026.102961_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.119984","article-title":"Phage display-identified PD-L1-binding peptides reinvigorate T-cell activity and inhibit tumor progression","volume":"247","author":"Gurung","year":"2020","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.nano.2026.102961_bb0060","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms Controlling PD-L1 Expression in Cancer","volume":"76","author":"Cha","year":"2019","journal-title":"Mol Cell"},{"issue":"8","key":"10.1016\/j.nano.2026.102961_bb0065","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.3390\/pharmaceutics14081581","article-title":"Recent Advances in Nanoparticles-Based Platforms Targeting the PD-1\/PD-L1 Pathway for Cancer Treatment","volume":"14","author":"Yu","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nano.2026.102961_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116203","article-title":"Tumor immunotherapy resistance: revealing the mechanism of PD-1 \/ PD-L1-mediated tumor immune escape","volume":"171","author":"Cui","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"23","key":"10.1016\/j.nano.2026.102961_bb0075","doi-asserted-by":"crossref","first-page":"19393","DOI":"10.18632\/oncotarget.5107","article-title":"The anticancer immune response of anti-PD-1\/PD-L1 and the genetic determinants of response to anti-PD-1\/PD-L1 antibodies in cancer patients","volume":"6","author":"Sui","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.nano.2026.102961_bb0080","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12943-023-01865-0","article-title":"Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation","volume":"22","author":"Chehelgerdi","year":"2023","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.nano.2026.102961_bb0085","doi-asserted-by":"crossref","DOI":"10.1186\/s12951-018-0392-8","article-title":"Nano based drug delivery systems: recent developments and future prospects","volume":"16","author":"Patra","year":"2018","journal-title":"J Nanobiotechnol"},{"issue":"4","key":"10.1016\/j.nano.2026.102961_bb0090","first-page":"513","article-title":"Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications","volume":"19","author":"Ortiz","year":"2021","journal-title":"Curr Neuropharmacol"},{"issue":"2","key":"10.1016\/j.nano.2026.102961_bb0095","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1021\/jm00368a016","article-title":"Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one, a novel broad-spectrum antitumor agent","volume":"27","author":"Stevens","year":"1984","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.nano.2026.102961_bb0100","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s11060-012-0906-4","article-title":"Radiotherapy and concomitant temozolomide may improve survival of elderly patients with glioblastoma","volume":"109","author":"Barker","year":"2012","journal-title":"J Neurooncol"},{"issue":"3","key":"10.1016\/j.nano.2026.102961_bb0105","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s11060-010-0427-y","article-title":"Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial","volume":"103","author":"Kim","year":"2011","journal-title":"J Neurooncol"},{"key":"10.1016\/j.nano.2026.102961_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2023.104568","article-title":"Therapeutic performance of temozolomide-loaded nanomaterials: A state-of-the-art","volume":"85","author":"Pourmadadi","year":"2023","journal-title":"J Drug Delivery Sci Technol"},{"key":"10.1016\/j.nano.2026.102961_bb0115","doi-asserted-by":"crossref","unstructured":"Geurts M, Berchtold L, Koenig F, Nabors B, Reardon DA, Tonn JC, Stupp R, Gorlia T, Weller M, Preusser M, EORTC Brain Tumor Group. Temozolomide chemotherapy for patients with newly diagnosed glioblastoma in the CENTRIC EORTC 26071-22072 and CORE trials: does time of administration matter?. Neuro-Oncology Practice 2025;12(2), 291\u2013300. doi:https:\/\/doi.org\/10.1093\/nop\/npaf006.","DOI":"10.1093\/nop\/npaf006"},{"issue":"1","key":"10.1016\/j.nano.2026.102961_bb0120","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11060-020-03598-2","article-title":"Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor","volume":"151","author":"Hotchkiss","year":"2021","journal-title":"J Neurooncol"},{"issue":"21","key":"10.1016\/j.nano.2026.102961_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e39984","article-title":"Research progress of drug resistance mechanism of temozolomide in the treatment of glioblastoma","volume":"10","author":"Wu","year":"2024","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.nano.2026.102961_bb0130","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s40478-025-02046-4","article-title":"Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights","volume":"13","author":"Li","year":"2021","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.nano.2026.102961_bb0135","first-page":"17","article-title":"Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review","volume":"4","author":"Singh","year":"2021","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.nano.2026.102961_bb0140","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920937612","article-title":"Efficacy of PD-1\/PD-L1 blockade monotherapy in clinical trials","volume":"12","author":"Zhao","year":"2020","journal-title":"Therapeutic advances in medical oncology"},{"key":"10.1016\/j.nano.2026.102961_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.653521","article-title":"Efficacy and Safety of Anti-PD-1\/PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence","volume":"12","author":"Qi","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.nano.2026.102961_bb0150","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40364-020-00212-5","article-title":"Resistance to PD-1\/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives","volume":"8","author":"Sun","year":"2020","journal-title":"Biomarker research"},{"key":"10.1016\/j.nano.2026.102961_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104426","article-title":"Evolving cancer resistance to anti-PD-1\/PD-L1 antibodies in melanoma: Comprehensive insights with future prospects","volume":"201","author":"Li","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"10.1016\/j.nano.2026.102961_bb0160","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00432-024-05808-0","article-title":"The efficiency and safety of temozolomide and PD-1\/L1 inhibitors in pretreated NSCLC with brain metastasis: a retrospective cohort","volume":"150","author":"Li","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"issue":"15","key":"10.1016\/j.nano.2026.102961_bb0165","article-title":"Temozolomide therapy for patients with non-small cell lung cancer, breast cancer, or melanoma brain metastases","volume":"28","author":"Naskhletashvili","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.nano.2026.102961_bb0170","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.7150\/thno.69119","article-title":"Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death","volume":"12","author":"Moon","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.nano.2026.102961_bb0175","doi-asserted-by":"crossref","unstructured":"L\u00facio KA, da Gra\u00e7a Rocha G, Mon\u00e7\u00e3o-Ribeiro LC, Fernandes J, Takiya CM, Gattass CR. Oleanolic acid initiates apoptosis in non-small cell lung cancer cell lines and reduces metastasis of a B16F10 melanoma model in vivo. PloS One 2011;6(12), e28596. doi:https:\/\/doi.org\/10.1371\/journal.pone.0028596.","DOI":"10.1371\/journal.pone.0028596"},{"key":"10.1016\/j.nano.2026.102961_bb0180","doi-asserted-by":"crossref","unstructured":"Dhanisha SS, Drishya S, Guruvayoorappan C. Pithecellobium dulce inhibits pulmonary metastasis induced by B16F10 melanoma cells in C57BL\/6 via regulating EGFR\/STAT\/NF\u03baB\/AKT signaling axis. J Food Biochem 2022;46(12), e14466. doi:https:\/\/doi.org\/10.1111\/jfbc.14466.","DOI":"10.1111\/jfbc.14466"},{"issue":"3s","key":"10.1016\/j.nano.2026.102961_bb0185","doi-asserted-by":"crossref","first-page":"S742","DOI":"10.5530\/ijper.55.3s.181","article-title":"Anti-metastatic and Anticancer Potentials of Synthesized Chalcones in B16-F10 Melanoma Cells Induced Metastatic Lung Cancer in C57BL\/6 Mice","volume":"55","author":"Kumar","year":"2021","journal-title":"Indian Journal of Pharmaceutical Education and Research"},{"key":"10.1016\/j.nano.2026.102961_bb0190","doi-asserted-by":"crossref","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis DL, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR, OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017;389(10066), 255\u2013265. doi:https:\/\/doi.org\/10.1016\/S0140-6736(16)32517-X.","DOI":"10.1016\/S0140-6736(16)32517-X"},{"issue":"10030","key":"10.1016\/j.nano.2026.102961_bb0195","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.nano.2026.102961_bb0200","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12964-023-01063-x","article-title":"Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions","volume":"21","author":"Watterson","year":"2023","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.nano.2026.102961_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2023.03.007","article-title":"FOXM1: A small fox that makes more tracks for cancer progression and metastasis","volume":"92","author":"Khan","year":"2023","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"10.1016\/j.nano.2026.102961_bb0210","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s12943-025-02400-z","article-title":"Overcoming resistance to anti-PD-L1 immunotherapy: mechanisms, combination strategies, and future directions","volume":"24","author":"Mandal","year":"2025","journal-title":"Mol Cancer"},{"issue":"2","key":"10.1016\/j.nano.2026.102961_bb0215","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s10549-013-2560-8","article-title":"Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry","volume":"139","author":"Inwald","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"17","key":"10.1016\/j.nano.2026.102961_bb0220","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.3390\/cancers13174455","article-title":"Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer","volume":"13","author":"Davey","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.nano.2026.102961_bb0225","article-title":"MGMT in TMZ-based glioma therapy: Multifaceted insights and clinical trial perspectives. Biochimica et Biophysica Acta (BBA) - Molecular","volume":"1871","author":"Shaw","year":"2024","journal-title":"Cell Res"},{"issue":"25","key":"10.1016\/j.nano.2026.102961_bb0230","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abn3471","article-title":"Temozolomide-induced guanine mutations create exploitable vulnerabilities of guanine-rich DNA and RNA regions in drug-resistant gliomas","volume":"8","author":"Tiek","year":"2022","journal-title":"Sci Adv"},{"issue":"7","key":"10.1016\/j.nano.2026.102961_bb0235","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1158\/2159-8290.CD-21-1434","article-title":"Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients","volume":"12","author":"Crisafulli","year":"2022","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.nano.2026.102961_bb0240","article-title":"Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma","volume":"4","author":"Daniel","year":"2022","journal-title":"Neurooncol Adv"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963426000626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963426000626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T07:26:17Z","timestamp":1784013977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963426000626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":48,"alternative-id":["S1549963426000626"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2026.102961","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationally designed, synthesized, and characterization of anti-PD-L1 peptide conjugated temozolomide self-assembled prodrug nanoparticles for targeted lung cancer chemoimmunotherapy","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2026.102961","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102961"}}